Clinical Research Directory

Inclusion Criteria: * Female, aged 40-65 years at time of enrollment * Confirmed menopausal status: (a) natural menopause (≥12 consecutive months of amenorrhea without other clinical cause), or (b) surgical menopause (bilateral oophorectomy with documented date of procedure) * Positive onboarding sleep screener: rates sleep quality as "Fairly Bad" or "Very Bad" AND reports sleep difficulty at least once per week in the prior month * PSQI global score \>5 at T0 baseline assessment (formal eligibility gate) * Owns and actively uses an Oura Ring Generation 4 at time of enrollment * Demonstrates ≥80% Oura Ring wear compliance in the 30 days prior to enrollment, confirmed via Alethios platform sync at onboarding * Willing to wear Oura Ring Generation 4 continuously for 42 nights throughout the study period * Willing to maintain stable diet, sleep habits, medications, and supplement use throughout the 42-day study period * No planned major disruptions to sleep schedule, shift work, or travel across ≥3 time zones during the study period * Access to a smartphone or computer to complete eConsent and digital questionnaires * Able to provide informed consent via the Alethios eConsent platform Exclusion Criteria: * Current use of prescription sleep medications (benzodiazepines, non-benzodiazepine hypnotics, doxepin, suvorexant) within 30 days of enrollment * Current use of melatonin supplements at doses \>1 mg/day within 14 days of enrollment * Diagnosis of a clinically significant sleep disorder requiring treatment (obstructive sleep apnea unless adequately treated and stable, restless legs syndrome, narcolepsy) * Diagnosis of a major psychiatric disorder currently requiring pharmacological treatment * Current use of hormone replacement therapy initiated within 90 days of enrollment, or any planned changes to HRT during the study (stable long-term HRT is acceptable) * Regular use of GABAergic, serotonergic, or sedating supplements (valerian, passionflower, ashwagandha, kava) within 14 days of enrollment * Shift work or schedule regularly requiring sleep between 06:00 and 22:00 * Planned travel across 3 or more time zones during the 42-day study period * Known allergy to lotus, rice, or related botanicals * Active cardiovascular, hepatic, renal, or neurological condition that in the PI's judgment would affect sleep or participant safety * Participation in another interventional study within 30 days of enrollment * In the opinion of the PI, any condition compromising participant safety or data integrity